155 related articles for article (PubMed ID: 21989258)
1. Modeling human cytochrome P450 2D6 metabolism and drug-drug interaction by a novel panel of knockout and humanized mouse lines.
Scheer N; Kapelyukh Y; McEwan J; Beuger V; Stanley LA; Rode A; Wolf CR
Mol Pharmacol; 2012 Jan; 81(1):63-72. PubMed ID: 21989258
[TBL] [Abstract][Full Text] [Related]
2. Human CYP2D6 and mouse CYP2Ds: organ distribution in a humanized mouse model.
Miksys SL; Cheung C; Gonzalez FJ; Tyndale RF
Drug Metab Dispos; 2005 Oct; 33(10):1495-502. PubMed ID: 16033950
[TBL] [Abstract][Full Text] [Related]
3. Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates.
Yu AM; Idle JR; Gonzalez FJ
Drug Metab Rev; 2004 May; 36(2):243-77. PubMed ID: 15237854
[TBL] [Abstract][Full Text] [Related]
4. The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse.
Corchero J; Granvil CP; Akiyama TE; Hayhurst GP; Pimprale S; Feigenbaum L; Idle JR; Gonzalez FJ
Mol Pharmacol; 2001 Dec; 60(6):1260-7. PubMed ID: 11723233
[TBL] [Abstract][Full Text] [Related]
5. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF
Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
[TBL] [Abstract][Full Text] [Related]
6. Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics.
Shen HW; Wu C; Jiang XL; Yu AM
Biochem Pharmacol; 2010 Jul; 80(1):122-8. PubMed ID: 20206139
[TBL] [Abstract][Full Text] [Related]
7. Potential role of CYP2D6 in the central nervous system.
Cheng J; Zhen Y; Miksys S; Beyoğlu D; Krausz KW; Tyndale RF; Yu A; Idle JR; Gonzalez FJ
Xenobiotica; 2013 Nov; 43(11):973-84. PubMed ID: 23614566
[TBL] [Abstract][Full Text] [Related]
8. Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles.
Bogni A; Monshouwer M; Moscone A; Hidestrand M; Ingelman-Sundberg M; Hartung T; Coecke S
Toxicol In Vitro; 2005 Aug; 19(5):621-9. PubMed ID: 15893449
[TBL] [Abstract][Full Text] [Related]
9. Molecular Dynamics Simulations Reveal Structural Differences among Allelic Variants of Membrane-Anchored Cytochrome P450 2D6.
Fischer A; Don CG; Smieško M
J Chem Inf Model; 2018 Sep; 58(9):1962-1975. PubMed ID: 30126275
[TBL] [Abstract][Full Text] [Related]
10. Human CYP2D6 Is Functional in Brain In Vivo: Evidence from Humanized CYP2D6 Transgenic Mice.
Tolledo C; Stocco MR; Miksys S; Gonzalez FJ; Tyndale RF
Mol Neurobiol; 2020 Jun; 57(6):2509-2520. PubMed ID: 32189192
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.
Sachse C; Brockmöller J; Bauer S; Roots I
Am J Hum Genet; 1997 Feb; 60(2):284-95. PubMed ID: 9012401
[TBL] [Abstract][Full Text] [Related]
12. Functional characterization of wild-type and 24 CYP2D6 allelic variants on gefitinib metabolism in vitro.
Fang P; Zheng X; He J; Ge H; Tang P; Cai J; Hu G
Drug Des Devel Ther; 2017; 11():1283-1290. PubMed ID: 28461741
[TBL] [Abstract][Full Text] [Related]
13. Farnesoid X Receptor Agonist Represses Cytochrome P450 2D6 Expression by Upregulating Small Heterodimer Partner.
Pan X; Lee YK; Jeong H
Drug Metab Dispos; 2015 Jul; 43(7):1002-7. PubMed ID: 25926433
[TBL] [Abstract][Full Text] [Related]
14. Propranolol is a mechanism-based inhibitor of CYP2D and CYP2D6 in humanized CYP2D6-transgenic mice: Effects on activity and drug responses.
Tolledo EC; Miksys S; Gonzalez FJ; Tyndale RF
Br J Pharmacol; 2020 Feb; 177(3):701-712. PubMed ID: 31648367
[TBL] [Abstract][Full Text] [Related]
15. Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms.
Yu A; Kneller BM; Rettie AE; Haining RL
J Pharmacol Exp Ther; 2002 Dec; 303(3):1291-300. PubMed ID: 12438554
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity.
Neafsey P; Ginsberg G; Hattis D; Sonawane B
J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):334-61. PubMed ID: 20183526
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.
Zanger UM; Raimundo S; Eichelbaum M
Naunyn Schmiedebergs Arch Pharmacol; 2004 Jan; 369(1):23-37. PubMed ID: 14618296
[TBL] [Abstract][Full Text] [Related]
18. Functional characterization of wild-type and 49 CYP2D6 allelic variants for N-desmethyltamoxifen 4-hydroxylation activity.
Muroi Y; Saito T; Takahashi M; Sakuyama K; Niinuma Y; Ito M; Tsukada C; Ohta K; Endo Y; Oda A; Hirasawa N; Hiratsuka M
Drug Metab Pharmacokinet; 2014; 29(5):360-6. PubMed ID: 24647041
[TBL] [Abstract][Full Text] [Related]
19. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.
Dorado P; Cáceres M; Pozo-Guisado E; Wong ML; Licinio J; Llerena A
Biotechniques; 2005 Oct; 39(10 Suppl):S571-4. PubMed ID: 18957039
[TBL] [Abstract][Full Text] [Related]
20. Functional characterization of 50 CYP2D6 allelic variants by assessing primaquine 5-hydroxylation.
Saito T; Gutiérrez Rico EM; Kikuchi A; Kaneko A; Kumondai M; Akai F; Saigusa D; Oda A; Hirasawa N; Hiratsuka M
Drug Metab Pharmacokinet; 2018 Dec; 33(6):250-257. PubMed ID: 30366777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
